AYTU BioPharma
AYTU
37 hedge funds and large institutions have $10.7M invested in AYTU BioPharma in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 5 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
9% more capital invested
Capital invested by funds: $9.81M → $10.7M (+$848K)
0.65% less ownership
Funds ownership: 37.02% → 36.37% (-0.65%)
5% less funds holding
Funds holding: 39 → 37 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Crown Advisors Management
Larkspur,
California
|
+$371K |
| 2 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$121K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$54.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$47.4K |
| 5 |
Two Sigma Investments
New York
|
+$37.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
-$80.6K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
-$76.4K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$54.8K |
| 4 |
SL
Sentinus LLC
Oak Brook,
Illinois
|
-$52K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$10.9K |
AYTU Hedge Fund Activity: Q1 2026 in Review
37 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2026, worth a combined $10.7M — up 8.7% from $9.81M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AYTU positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Crown Advisors Management, opening a new position worth an estimated $371K. The largest seller was FNY Investment Advisers, cutting an estimated $80.6K.
- 37 institutional investors held AYTU BioPharma (AYTU) as of Q1 2026, down from 39 in Q4 2025.
- Funds reported $10.7M of AYTU BioPharma stock for Q1 2026, up 8.7% quarter-over-quarter.
- 6 funds opened new AYTU BioPharma positions in Q1 2026 and 5 closed out, a net change of +1 holder.
- The largest AYTU BioPharma buyer in Q1 2026 was Crown Advisors Management, an estimated $371K added.
- The largest AYTU BioPharma seller in Q1 2026 was FNY Investment Advisers, an estimated $80.6K sold.
Based on aggregated 13F filings for Q1 2026.